Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel
Published in
Cancer Chemotherapy and Pharmacology, October 2014
Pharmacology, Toxicology and Pharmaceutical Science
2
10%
Business, Management and Accounting
2
10%
Nursing and Health Professions
1
5%
Other
1
5%
Unknown
6
29%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 June 2016.
All research outputs
#19,221,261
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#2,044
of 2,501 outputs
Outputs of similar age
#185,640
of 258,012 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#20
of 29 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 11th percentile – i.e., 11% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 258,012 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.
